Chen P, Nirula A, Heller B, et al. - Virus-neutralizing monoclonal antibodies are predicted to lower viral load, reduce symptoms, and avert hospitalization among patients with coronavirus disease 2019 (Covid-19). In this ongoing phase 2 trial, researchers randomly assigned 452 patients with recently diagnosed mild or moderate Covid-19 to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo. The interim analysis of this trial suggested that one of three doses of neutralizing antibody LY-CoV555 accelerate the natural reduction in viral load over time, whereas the other doses did not by day 11.